Category: Pharmaceutical Industry
-
FTC urges Fourth Circuit to reject Amgen plea to shield Roche patent acquisition: deal âthreatens to upendâ long-settled antitrust framework
The U.S. Federal Trade Commission has filed an amicus brief in an antitrust case between CareFirst and Amgen, urging the Fourth Circuit to reject Amgenâs bid to shield its acquisition of pending patent applications from antitrust scrutiny, as such procurements violate the Sherman Act and are not immunized by the Noerr-Pennington doctrine.
-
Chinaâs top court overturns Nefecon generic PI despite U.S. Paragraph III-style no-launch pledgeÂ
A Chinese generic of Nefecon obtained formal approval after promising not to launch until patent expiry, then used that approval to seek procurement listings. Chinaâs top court nevertheless held that the broken Paragraph III-style pledge was a regulatory breach – not an admission of patent infringement.
-
EWHC hinders Accordâs plans to launch Entresto competing product in Novartis patent dispute
Mr. Justice Meade of the High Court of Justice for England & Wales has held that all of Accordâs âattacksâ on a Novartis Entresto patent have failed, and its own intended competing product would infringe the defendantâs supplementary protection certificate.
-
Patent Litigation Europe returns for 2027, building on last year’s rebrand into three co-located tracksÂ
Speakers already confirmed for the event include Hon. Emmanuel Gouge and AleĆĄ Zalar of the UPC, Judge Oliver Schön of the Munich Regional Court, Abbottâs Gael Tisack, Ericssonâs Gabriele Mohsler, Nokiaâs Clemens Heusch, and SIM IPâs Erich Spangenberg.
-
U.S. GLP-1 patent docket grows with raft of new complaints from Eli Lilly, Novo Nordisk
This could well be the start of a wide-ranging, multi-jurisdictional campaign by Eli Lilly to defend its rights around Mounjaro and Zepbound.
-
UPC keeps Merz infringement case despite earlier French filing
The UPCâs Paris LD rejected Viatrisâ attempt to halt Merzâs infringement action in favor of parallel proceedings before a French national court. The ruling clarifies when earlier national proceedings prevent the UPC from continuing with an infringement action.
-
âThe future of medicine and diagnosticsâ: behind the patent enforcement strategy of biotech tools company SeerÂ
Seerâs VP of Legal, George Fox, discusses the challenges that its patent portfolio has recently overcome, and the enforcement campaign it has launched in the U.S.Â
-
Canada’s Supreme Court clarifies (un)patentability of medical treatment methods in landmark decision
Janssen and Pharmascience have been locked in litigation since 2020 over the former’s antipsychotic patent, which includes claims directed towards dosage regimens.
-
Covid-19 vaccine makers Moderna and Pfizer hit with Sanofi suits over mRNA delivery tech
Sanofi and Translate Bio effectively abandoned their own Covid-19 vaccine effort in 2021 after the former acquired the latter.
-
Federal Circuit upholds decision to throw out $107.5M patent infringement verdict against AstraZeneca
The precedential decision, confirming the invalidation of two of Pfizer subsidiary Wyethâs cancer drug-related patents, held that the plaintiff not only failed to rebut evidence on certain issues, but its own experts agreed against it.